vedroprevir

Vedroprevir is a small molecule, investigational antiviral drug developed as a direct-acting inhibitor of the hepatitis C virus (HCV) NS3 serine protease. By binding to and inhibiting the NS3 protease, vedroprevir blocks cleavage of the HCV polyprotein, thereby preventing formation of the viral replication complex and interfering with viral assembly and release. Vedroprevir has demonstrated potent activity against HCV genotype 1 in preclinical and clinical studies but is less effective as monotherapy due to rapid resistance development; it must be used in combination with other direct acting antivirals (DAAs) for optimal efficacy. The drug reached phase II clinical trials for chronic hepatitis C infection[1][2][3][4][5].

Other names

vedroprevir